PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2005 March; 6(1): E49–E55.
Published online 2005 September 20. doi:  10.1208/pt060110
PMCID: PMC2750411

Formulation and evaluation of mucoadhesive glipizide microspheres

Abstract

The purpose of this research was to formulate and system-atically evaluate in vitro and in vivo performances of mucoadhesive microspheres of glipizide. Glipizide microspheres containing chitosan were prepared by simple emulsification phase separation technique using glutaraldehyde as a cross-linking agent. Results of preliminary trials indicate that volume of cross-linking agent, time for cross-linking, polymer-to-drug ratio, and speed of rotation affected characteristics of microspheres. Microspheres were discrete, spherical, and free flowing. The microspheres exhibited good mucoadhesive property in the in vitro wash-off test and also showed a high percentage drug entrapment efficiency. A 32 full factorial design was employed to study the effect of independent variables, polymer-to-drug ratio (X1), and stirring speed (X2) on dependent variables percentage mucoadhesion, t80, drug entrapment efficiency, and swelling index. The best batch exhibited a high drug entrapment efficiency of 75% and a swelling index of 1.42; percentage mucoadhesion after 1 hour was 78%. The drug release was also sustained for more than 12 hours. The polymer-to-drug ratio had a more significant effect on the dependent variables. In vivo testing of the mucoadhesive microspheres to albino Wistar rats demonstrated significant hypoglycemic effect of glipizide.

Keywords: chitosan, mucoadhesive microspheres, glipizide, factorial design, in vivo study

Full Text

The Full Text of this article is available as a PDF (218K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Woo BH, Jiang G, Jo YW, DeLuca PP. Preparation and characterization of a composite PLGA and poly (acryloyl hydroxymethyl starch) microsphere system for protein delivery. Pharm Res. 2001;18:1600–1606. doi: 10.1023/A:1013090700443. [PubMed] [Cross Ref]
2. Capan Y, Jiang G, Giovagnoli S, DeLuca PP. Preparation and characterization of poly (D,L-lactide-co-glycolide) microsphere for controlled release of human growth hormone. AAPS PharmSciTech. 2003;4:E28–E28. doi: 10.1208/pt040228. [PMC free article] [PubMed] [Cross Ref]
3. Gohel MC, Amin AF. Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. J Control Release. 1998;51:115–122. doi: 10.1016/S0168-3659(97)00102-8. [PubMed] [Cross Ref]
4. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm. 2003;255:13–32. doi: 10.1016/S0378-5173(03)00087-5. [PubMed] [Cross Ref]
5. Ikeda K, Murata K, Kobayashi M, Noda K. Enhancement of bioavailability of dopamine via nasal route in beagle dogs. Chem Pharm Bull (Tokyo) 1992;40:2155–2158. [PubMed]
6. Nagai T, Nishimoto Y, Nambu N, Suzuki Y, Sekine K. Powder dosage form of insulin for nasal administration. J Control Release. 1984;1:15–22. doi: 10.1016/0168-3659(84)90017-8. [Cross Ref]
7. Ilium L, Farraj NF, Critchley H, Davis SS. Nasal administration of gentamicin using a novel microsphere delivery system. Int J Pharm. 1988;46:261–265. doi: 10.1016/0378-5173(88)90087-7. [Cross Ref]
8. Schaefer MJ, Singh J. Effect of isopropyl myristic acid ester on the physical characteristics and in vitro release of etoposide from PLGA microspheres. AAPS PharmSciTech. 2000;1:E32–E32. doi: 10.1208/pt010432. [PMC free article] [PubMed] [Cross Ref]
9. Rao SB, Sharma CP. Use of chitosan as biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res. 1997;34:21–28. doi: 10.1002/(SICI)1097-4636(199701)34:1<21::AID-JBM4>3.0.CO;2-P. [PubMed] [Cross Ref]
10. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm. 1992;78:43–48. doi: 10.1016/0378-5173(92)90353-4. [Cross Ref]
11. Henriksen I, Green KL, Smart JD, Smistad G, Karlsen J. Bioadhesion of hydrated chitosans: an in vitro and in vivo study. Int J Pharm. 1996;145:231–240. doi: 10.1016/S0378-5173(96)04776-X. [Cross Ref]
12. Chowdary KPR, Rao YS. Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: a technical note. AAPS PharmSciTech. 2003;4:E39–E39. doi: 10.1208/pt040339. [PMC free article] [PubMed] [Cross Ref]
13. Thanoo BC, Sunny MC, Jayakrishnan A. Cross-linked chitosan microspheres: preparation and evaluation as a matrix for the controlled release of pharmaceuticals. J Pharm Pharmacol. 1992;44:283–286. [PubMed]
14. Hari PR, Chandy T, Sharma CP. Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoin. J Microencapsul. 1996;13:319–329. doi: 10.3109/02652049609026019. [PubMed] [Cross Ref]
15. Liu LS, Liu SQ, Ng SY, Froix M, Heller J. Controlled release of interleukin 2 for tumour immunotherapy using alginate/chitosan porous microspheres. J Control Release. 1997;43:65–74. doi: 10.1016/S0168-3659(96)01471-X. [Cross Ref]
16. Patel JK, Bodar MS, Amin AF, Patel MM. Formulation and optimization of mucoadhesive microspheres of metoclopramide. Ind J Pharm Sci. 2004;66:300–305.
17. Dubey RR, Parikh RH. Two-stage optimization process for formulation of chitosan microspheres. AAPS PharmSciTech. 2004;5:E5–E5. doi: 10.1208/pt050105. [PMC free article] [PubMed] [Cross Ref]
18. Foster RH, Plosker GL. Glipizide: a review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics. 2000;18:289–306. doi: 10.2165/00019053-200018030-00008. [PubMed] [Cross Ref]
19. Thombre AG, Denoto AR, Gibbes DC. Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients. J Control Release. 1999;60:333–341. doi: 10.1016/S0168-3659(99)00086-3. [PubMed] [Cross Ref]
20. Chowdary KPR, Balatripura G. Design and in vitro evaluation of mucoadhesive controlled release oral tablets of glipizide. Ind J Pharm Sci. 2003;65:591–594.
21. The United States Pharmacopeia. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2003. pp. 859–859.
22. Eugene L. Milling. In: Lachman L, Liberman HA, editors. The Theory and Practice of Industrial Pharmacy. 2nd ed. Mumbai, India: Varghese Publishing House; 1991. pp. 26–27.
23. The United States Pharmacopeia. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2003. pp. 2528–2528.
24. El-Gibaly I. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int J Pharm. 2002;249:7–21. doi: 10.1016/S0378-5173(02)00396-4. [PubMed] [Cross Ref]
25. Lehr CM, Bowstra JA, Tukker JJ, Junginger HE. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat. J Control Release. 1990;13:51–62. doi: 10.1016/0168-3659(90)90074-4. [Cross Ref]
26. Nelson KG, Wang LY. Determination of time course of tablet disintegration II: method using continuous functions. J Pharm Sci. 1961;67:86–89. doi: 10.1002/jps.2600670122. [PubMed] [Cross Ref]
27. Lee JW, Park JH, Robinson JR. Bioadhesive-based dosage forms: the next generation. J Pharm Sci. 2000;89:850–866. doi: 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G. [PubMed] [Cross Ref]
28. Bamba M, Puisieux F, Marty JP, Carstensen JT. Release mechanisms in gelforming sustained release preparations. Int J Pharm. 1979;2:307–315. doi: 10.1016/0378-5173(79)90037-1. [Cross Ref]
29. Kahn CR, Shechter Y. Oral hypoglycemic agents and the pharmacology of the endocrine pancreas. In: Theodore WR, Alan SN, Taylor P, Gilman AG, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: McGraw-Hill; 1991. pp. 1461–1495.
30. Berelowitz M, Fischette C, Cefelu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care. 1994;17:1460–1464. doi: 10.2337/diacare.17.12.1460. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists